ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 533

Predictive Significance of CCL21 and CXCL13 Levels in the Minor Salivary Glands of Patients with Sjögren’s Syndrome

Kyung-Eun Lee1, Dong-Jin Park1 and Shin-Seok Lee2, 1Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, 2Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjogren's Syndrome: Pathophysiology

Session Type: Abstract Submissions (ACR)

Background/Purpose

Chemokines, which control inflammatory cell migration, have been shown to play important roles in the inflammatory processes associated with Sjögren’s Syndrome (SS). CCL21 and CXCL13 within the lymphocytic infiltrate characteristic of the condition have been reported to contribute to ectopic lymphoneogenesis. In the current study, we investigated whether the laboratory and clinical manifestations of SS patients were associated with CCL21 and CXCL13 expression levels in the minor salivary gland.

Methods

We obtained sociodemographic data on a total of 106 SS patients, documented glandular and extraglandular manifestations of the disease, performed minor salivary gland biopsies, and analyzed laboratory findings. EULAR index values of SS disease activity (ESSDAI values) at the time of biopsy, and SS disease damage index (SSDDI) values, were also noted. An immunohistochemical approach was used to (semiquantitatively) measure the expression levels of CCL21 and CXCL13 in the minor salivary glands.

Results

The minor salivary glands of SS patients stained positively for CCL21 and CXCL13 in 46.2% (49/106) and 70.7% (75/106) of all cases, respectively. Higher-level expression of CCL21 was associated with an elevated ESR, an increased IgG level, elevated anti-SS-A and -SS-B titers, a higher focus score, and a greater ESSDAI value at the time of biopsy. Higher-level expression of CXCL13 was associated with an elevated ESR, an increased IgG level, elevated anti-SS-A and -SS-B titers, a rise in the level of rheumatoid factor, a higher focus score, and a greater ESSDAI value at the time of biopsy. In patients with extraglandular manifestations of SS, the prevalence of lymphadenopathy tended to rise with an increase in the level of CCL21.

Conclusion

The expression levels of CCL21 and CXCL13 within the lymphocytic infiltrates of SS patients were associated with several laboratory features of the disease, lymphadenopathy, and the extent of clinical disease activity. CCL21 and CXCL13 levels should serve as useful markers predicting SS disease activity and prognosis.


Disclosure:

K. E. Lee,
None;

D. J. Park,
None;

S. S. Lee,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictive-significance-of-ccl21-and-cxcl13-levels-in-the-minor-salivary-glands-of-patients-with-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology